UNITEX
12.1.2022 09:32:08 CET | Business Wire | Press release
UNITEX Corporation (Representative: Emi Kosugi, President / Office: Machida, Tokyo), the leader in the computer storage space for over 30 years, is pleased to announce today that its popular USB LTO tape drive will be available with LTO-9 technology in the spring of 2022. It features USB connectivity, a native storage capacity of 18TB and compressed storage capacity at 2.5:1 of 45TB, and a data transfer rate of up to 300MB/second.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220111005635/en/
UNITEX USB LTO-9 highlights
-
LTO-9 tape archiving solution with the world’s only USB connectivity
You can use USB LTO-9 by connecting to laptop PCs and other USB devices to store large volumes of data anywhere, conveniently, with small IT-invested. Both half-height (HH) and full-height (FH) drives are available.
-
Increased capacity. Increased speed.
Offering up to 45TB of storage capacity (18TB for non-compressed data), a 50% greater capacity than LTO-8. Transfer speeds with USB connection reach up to 300MB/ second, a 25% faster than the previous USB LTO-8.
-
Offering protection against cybercrime
LTO tape can be stored offline and off-network, creating a physical “air gap” of protection to minimize the risk of data exposure to cyberattacks. In addition UNITEX archiving software protects your data safely with tamper-proof by hash value and encryption functions.
-
Lower environmental impact
LTO tape and USB connectivity have a significantly lower environmental impact as there is no need to have it constantly powered-on during data storage, thereby reducing CO2 emissions generated by 94% (*1) when compared to hard disk drives (HDDs). *1 Source: JEITA tape storage committee
About UNITEX Corporation
UNITEX Corporation has specialized in the computer storage space since it was founded in 1990. Over the years, UNITEX has developed various driver and application software, greatly increasing interoperability and making storage devices compatible across the entire spectrum of computer operating systems. This solid history and experiences make UNITEX an extremely reliable data storage solution provider.
Main product categories
- The world's only USB LTO data storage system
- Financial system solutions for high-security data conversion and migration
- Multi-optical disk systems with high-performance robot arms
Company Name: UNITEX Corporation
Representative: Emi Kosugi, President
Headquarter: 2-2-4 Nakamachi, Machida, Tokyo, Japan
Establishment: October, 1990
Capital: US$800,000
URL: https://www.unitex.co.jp/en
View source version on businesswire.com: https://www.businesswire.com/news/home/20220111005635/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom